Journal Publications

Project Data Sphere's success is ultimately measured by the practice-changing scientific insights discovered by the research community. We are proud to share the following list of peer-accepted publications, and we are grateful to the data providers, research scientists, and patients that make this possible.

Author(s)sort descending Date Article Title Journal

Guru Sonpavdea, Gregory R.Pond, Arnoud J.Templeton, Abderrahim Fandi, Bertrand Tombale, Mark Rosenthal, Andrew J.Armstrong, Daniel P.Petrylakh

 June 2016 Association Between RECIST Changes and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Receiving Docetaxel European Urology

H-G Eichler, B. Bloechl-Daum, P. Bauer, F. Bretz, J. Brown, LV Hampson, P. Honig, M. Krams, H. Leufkens, R. Lim, M.M. Lumpkin, M.J. Murphy, F. Pignatti, M. Posch, S. Schneeweiss, M. Trusheim, F. Koenig

 October 2016 "Threshold-crossing": A Useful Way to Establish the Counterfactual in Clinical Trials? Clinical Pharmacology & Therapeutics

Hani Oweira, Anway Giryes, Meinrad Mannhart, Michael Decker, and Omar Abdel-Rahman

 August 2018 Impact of Time to Start Systemic Therapy on the Outcomes of Patients with Metastatic Colorectal Cancer Treated with First Line FOLFOX Chemotherapy; a Patient-Level Pooled Analysis of Two Clinical Trials Expert Review of Gastroenterology and Hepatology

Hirotaka Miyashita, Christina Cruz, Cardinale Smith

 August 2020 Risk factors of skeletal-related events in patients with bone metastasis from non-small cell lung cancer undergoing treatment with zoledronate—a post hoc analysis of a randomized clinical trial Supportive Care in Cancer

Hirotaka Miyashita, Christina Cruz, Stephen Malamud

 May 2020 Risk factors for skeletal-related events in patients with bone metastasis from breast cancer undergoing treatment with zoledronate Breast Cancer Research and Treatment

Hirotaka Miyashita, Christina Cruz, Vaibhav Patel 

 August 2021 Risk factors of skeletal-related events in patients with bone metastatic castration-resistant prostate cancer undergoing treatment with zoledronate Supportive Care in Cancer

Hiroyuki Saeki, Takuji Komeda, Risa Tanaka, Yuki Yamatani & Hironori Sakai 

 March 2022 Estimation of a Suitable Number of Patients for Selective Safety Data Collection (ICH E19 Draft Guideline): When is the Safety Profile of a Drug Well Characterized? Therapeutic Innovation & Regulatory Science

Hitesh B. Mistry, Gabriel Helmlinger, Nidal Al-Huniti, Karthick Vishwanathan, James Yates

 April 2019 Resistance Models to EGFR Inhibition and Chemotherapy in Non-Small Cell Lung Cancer Via Analysis of Tumour Size Dynamics Cancer Chemotherapy and Pharmacology

J. C. Angulo, J. P. Ciria Santos, A. Gómez-Caamaño, R. Poza de Celis, J. L. González Sala, J. M. García Garzón, J. A. Galán-Llopis, M. Pérez Sampietro, V. Perrot & J. Planas Morin on behalf of ANARESISTANCE study group

 September 2022 Development of castration resistance in prostate cancer patients treated with luteinizing hormone-releasing hormone analogues (LHRHa): results of the ANARESISTANCE study SpringerLink

Jean Coquet, PhD; Nicolas Bievre, MS; Vincent Billaut, MS; Martin Seneviratne, MD; Christopher J. Magnani, MPhil; Selen Bozkurt, PhD; James D. Brooks, MD; Tina Hernandez-Boussard, PhD

 February 2021 Assessment of a Clinical Trial–Derived Survival Model in Patients With Metastatic Castration-Resistant Prostate Cancer JAMA Network Open

Jeffrey West, Yongqian Ma, Paul K. Newton

 October 2018 Capitalizing on Competition: An Evolutionary Model of Competitive Release in Metastatic Castration Resistant Prostate Cancer Treatment Journal of Theoretical Biology

Jian-Sin Lee, Wei Jeng

 October 2022 Integrated but Isolated: Implications from a Systematic Review of the Access Control Ecosystem for Individual Participant Data in Clinical Studies John Wiley & Sons, Ltd (asis&t)

Jiang Y, Cai D, Shi S

 April 2022 Indirect Comparisons via Sorafenib for the Comparative Effectiveness of Two PD-1/PD-L1 Inhibitors to Treat Advanced Hepatocellular Carcinoma Patients without Prior Systemic Therapies Dovepress

Jiawei Zhou, Quefeng Li, Yanguang Cao

 February 2021 Spatiotemporal Heterogeneity Across Metastases and Organ-Specific Response Informs Drug Efficacy and Patient Survival in Colorectal Cancer Cancer Research

Pages